Company Product Description Indication Status
Ascendis Pharma A/S, of Copenhagen Transcon hGH (lonapegsomatropin) Long-acting prodrug of somatropin Pediatric growth hormone deficiency FDA accepted the BLA and indicated that it doesn't currently plan to hold an advisory committee meeting to discuss the application; PDUFA action date is June 25, 2021
Eli Lilly and Co., of Indianapolis Trulicity (dulaglutide) Glucagon-like peptide-1 analogue Type 2 diabetes FDA approved 2 higher doses of the drug
Kite Pharma Inc., a unit of Foster City, Calif.-based Gilead Sciences Inc. Yescarta (axicabtagene ciloleucel) Autologous CAR T-cell therapy targeting CD19 Relapsed or refractory follicular lymphoma and marginal zone lymphoma after 2 or more lines of systemic therapy Submitted a supplemental BLA to the FDA

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments